Previous 10 | Next 10 |
home / stock / azncf / azncf news
2020 has been a crazy year. We have experienced an unprecedented money flow into growth/tech stocks , disfavoring value stocks (stocks which are trading below their fundamentals based on their earnings and/or dividends). In fact, the Nasdaq ( QQQ ) is up ~18% year-to-date compared to a decl...
Investment Thesis The much-awaited peer-reviewed data of mRNA-1273, the COVID-19 vaccine candidate of Moderna, Inc. ( MRNA ), has left many questions unanswered. Though the vaccine has been safe and produced neutralizing antibodies, the Phase 3 trial will look for the vaccine's clinical ef...
Quick Take AlloVir ( ALVR ) intends to raise $251 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is a mid stage firm developing drug treatments for virus conditions. ALVR is preparing to enter Phase 3 trials and has an e...
Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Quick Take AlloVir ( ALVR ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is a mid-stage clinical biopharma firm developing treatments for various virus infections. ALVR is seeking funding to advance its lead cand...
Many investors dumped BELLUS Health ( BLU ) because the company's Phase 2 trial did not offer good results. They appear to forget that BELLUS Health is planning to execute Phase 2b results. If the results are a bit better, the share price will most likely creep up. Besides, the company is targ...
Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...
Mortality defines the human condition. - Drew Gilpin Faust Investor interest in the biotech industry will likely endure for a long time If you're part of my Lead-Lag report-reading cohort, you'll know that I've been providing regular updates on the developments and the performance of o...
Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...